Autopsy report · NCT04511650

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

“After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges associated with recruiting and monitoring patients in the current pandemic environment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 4 months before it stopped.
• 31 participants enrolled.
• Results were posted on the registry 2 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

EyePoint Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

COVID-19; Acute Respiratory Distress Syndrome (ARDS)

Interventions

Razuprotafib Subcutaneous Solution; Placebo Subcutaneous Solution

Participants

31

Sites

7

Countries

United States

Trials that died the same way

• The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study
  “Due to difficulty in recruiting patients, the Sponsor decided to prematurely stop the study” (75% match in meaning)
• RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
  “The sponsor's clinical program for the agent used in this study was discontinued.” (75% match in meaning)
• Assessment of the Utility of BIOMONITOR to Identify Atrial Fibrillation (AF) in Ablation Candidates Using Precise AF Detection
  “This study was terminated by the sponsor since study timelines were extended significantly due to slow enrollment, partly influenced by the COVID-19 pandemic.” (74% match in meaning)
• Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria
  “Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus disease 2019 (COVID-19) pandemic.” (73% match in meaning)
• Correlating the OA Knee Microenvironment to Outcomes After Regenexx-SD Treatment: A Multi-Site Study
  “sponsor discontinued study-impacted by COVID” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.